2023-01-012023-12-312023-12-31false12510491CELLSWAY LIMITED2024-10-0426511iso4217:GBPxbrli:pure125104912023-01-01125104912023-12-31125104912023-01-012023-12-31125104912022-01-01125104912022-12-31125104912022-01-012022-12-3112510491bus:SmallEntities2023-01-012023-12-3112510491bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3112510491bus:FullAccounts2023-01-012023-12-3112510491bus:PrivateLimitedCompanyLtd2023-01-012023-12-3112510491core:WithinOneYear2023-12-3112510491core:AfterOneYear2023-12-3112510491core:WithinOneYear2022-12-3112510491core:AfterOneYear2022-12-3112510491core:ShareCapital2023-12-3112510491core:SharePremium2023-12-3112510491core:RevaluationReserve2023-12-3112510491core:OtherReservesSubtotal2023-12-3112510491core:RetainedEarningsAccumulatedLosses2023-12-3112510491core:ShareCapital2022-12-3112510491core:SharePremium2022-12-3112510491core:RevaluationReserve2022-12-3112510491core:OtherReservesSubtotal2022-12-3112510491core:RetainedEarningsAccumulatedLosses2022-12-3112510491core:LandBuildings2023-12-3112510491core:PlantMachinery2023-12-3112510491core:Vehicles2023-12-3112510491core:FurnitureFittings2023-12-3112510491core:OfficeEquipment2023-12-3112510491core:NetGoodwill2023-12-3112510491core:IntangibleAssetsOtherThanGoodwill2023-12-3112510491core:ListedExchangeTraded2023-12-3112510491core:UnlistedNon-exchangeTraded2023-12-3112510491core:LandBuildings2022-12-3112510491core:PlantMachinery2022-12-3112510491core:Vehicles2022-12-3112510491core:FurnitureFittings2022-12-3112510491core:OfficeEquipment2022-12-3112510491core:NetGoodwill2022-12-3112510491core:IntangibleAssetsOtherThanGoodwill2022-12-3112510491core:ListedExchangeTraded2022-12-3112510491core:UnlistedNon-exchangeTraded2022-12-3112510491core:LandBuildings2023-01-012023-12-3112510491core:PlantMachinery2023-01-012023-12-3112510491core:Vehicles2023-01-012023-12-3112510491core:FurnitureFittings2023-01-012023-12-3112510491core:OfficeEquipment2023-01-012023-12-3112510491core:NetGoodwill2023-01-012023-12-3112510491core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112510491core:ListedExchangeTraded2023-01-012023-12-3112510491core:UnlistedNon-exchangeTraded2023-01-012023-12-3112510491core:MoreThanFiveYears2023-01-012023-12-3112510491core:Non-currentFinancialInstruments2023-12-3112510491core:Non-currentFinancialInstruments2022-12-3112510491dpl:CostSales2023-01-012023-12-3112510491dpl:DistributionCosts2023-01-012023-12-3112510491core:LandBuildings2023-01-012023-12-3112510491core:PlantMachinery2023-01-012023-12-3112510491core:Vehicles2023-01-012023-12-3112510491core:FurnitureFittings2023-01-012023-12-3112510491core:OfficeEquipment2023-01-012023-12-3112510491dpl:AdministrativeExpenses2023-01-012023-12-3112510491core:NetGoodwill2023-01-012023-12-3112510491core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112510491dpl:GroupUndertakings2023-01-012023-12-3112510491dpl:ParticipatingInterests2023-01-012023-12-3112510491dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3112510491core:ListedExchangeTraded2023-01-012023-12-3112510491dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3112510491core:UnlistedNon-exchangeTraded2023-01-012023-12-3112510491dpl:CostSales2022-01-012022-12-3112510491dpl:DistributionCosts2022-01-012022-12-3112510491core:LandBuildings2022-01-012022-12-3112510491core:PlantMachinery2022-01-012022-12-3112510491core:Vehicles2022-01-012022-12-3112510491core:FurnitureFittings2022-01-012022-12-3112510491core:OfficeEquipment2022-01-012022-12-3112510491dpl:AdministrativeExpenses2022-01-012022-12-3112510491core:NetGoodwill2022-01-012022-12-3112510491core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3112510491dpl:GroupUndertakings2022-01-012022-12-3112510491dpl:ParticipatingInterests2022-01-012022-12-3112510491dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3112510491core:ListedExchangeTraded2022-01-012022-12-3112510491dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3112510491core:UnlistedNon-exchangeTraded2022-01-012022-12-3112510491core:NetGoodwill2023-12-3112510491core:IntangibleAssetsOtherThanGoodwill2023-12-3112510491core:LandBuildings2023-12-3112510491core:PlantMachinery2023-12-3112510491core:Vehicles2023-12-3112510491core:FurnitureFittings2023-12-3112510491core:OfficeEquipment2023-12-3112510491core:AfterOneYear2023-12-3112510491core:WithinOneYear2023-12-3112510491core:ListedExchangeTraded2023-12-3112510491core:UnlistedNon-exchangeTraded2023-12-3112510491core:ShareCapital2023-12-3112510491core:SharePremium2023-12-3112510491core:RevaluationReserve2023-12-3112510491core:OtherReservesSubtotal2023-12-3112510491core:RetainedEarningsAccumulatedLosses2023-12-3112510491core:NetGoodwill2022-12-3112510491core:IntangibleAssetsOtherThanGoodwill2022-12-3112510491core:LandBuildings2022-12-3112510491core:PlantMachinery2022-12-3112510491core:Vehicles2022-12-3112510491core:FurnitureFittings2022-12-3112510491core:OfficeEquipment2022-12-3112510491core:AfterOneYear2022-12-3112510491core:WithinOneYear2022-12-3112510491core:ListedExchangeTraded2022-12-3112510491core:UnlistedNon-exchangeTraded2022-12-3112510491core:ShareCapital2022-12-3112510491core:SharePremium2022-12-3112510491core:RevaluationReserve2022-12-3112510491core:OtherReservesSubtotal2022-12-3112510491core:RetainedEarningsAccumulatedLosses2022-12-3112510491core:NetGoodwill2022-01-0112510491core:IntangibleAssetsOtherThanGoodwill2022-01-0112510491core:LandBuildings2022-01-0112510491core:PlantMachinery2022-01-0112510491core:Vehicles2022-01-0112510491core:FurnitureFittings2022-01-0112510491core:OfficeEquipment2022-01-0112510491core:AfterOneYear2022-01-0112510491core:WithinOneYear2022-01-0112510491core:ListedExchangeTraded2022-01-0112510491core:UnlistedNon-exchangeTraded2022-01-0112510491core:ShareCapital2022-01-0112510491core:SharePremium2022-01-0112510491core:RevaluationReserve2022-01-0112510491core:OtherReservesSubtotal2022-01-0112510491core:RetainedEarningsAccumulatedLosses2022-01-0112510491core:AfterOneYear2023-01-012023-12-3112510491core:WithinOneYear2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112510491core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3112510491core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3112510491core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3112510491core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3112510491core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3112510491bus:Director12023-01-012023-12-3112510491bus:Director22023-01-012023-12-3112510491bus:Director32023-01-012023-12-3112510491bus:Director42023-01-012023-12-31

CELLSWAY LIMITED

Registered Number
12510491
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

CELLSWAY LIMITED
Company Information
for the year from 1 January 2023 to 31 December 2023

Directors

Arif Alper Karagoz
Haluk Kulah
Ebru Ozgur
Ozge Zorlu

Registered Address

293 Green Lanes
Palmers Green
N13 4XS

Registered Number

12510491 (England and Wales)
CELLSWAY LIMITED
Balance Sheet as at
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Intangible assets3614,064878,810
614,064878,810
Current assets
Debtors379349
Current asset investments480,00080,000
Cash at bank and on hand118,341168,931
198,720249,280
Creditors amounts falling due within one year5(833,365)(1,130,375)
Net current assets (liabilities)(634,645)(881,095)
Total assets less current liabilities(20,581)(2,285)
Net assets(20,581)(2,285)
Capital and reserves
Called up share capital80,00080,000
Profit and loss account(100,581)(82,285)
Shareholders' funds(20,581)(2,285)
The financial statements were approved and authorised for issue by the Board of Directors on 4 October 2024, and are signed on its behalf by:
Ebru Ozgur
Director
Haluk Kulah
Director
Ozge Zorlu
Director

Registered Company No. 12510491
CELLSWAY LIMITED
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.Average number of employees

20232022
Average number of employees during the year11
3.Intangible assets

Other

Total

££
Cost or valuation
At 01 January 23878,810878,810
Transfers(264,746)(264,746)
At 31 December 23614,064614,064
Net book value
At 31 December 23614,064614,064
At 31 December 22878,810878,810
4.Current asset investments
5.Creditors: amounts due within one year

2023

2022

££
Trade creditors / trade payables747,6591,130,375
Bank borrowings and overdrafts85,706-
Total833,3651,130,375